: FDA advisers narrowly back accelerated approval of Sarepta gene therapy
: FDA advisers narrowly back accelerated approval of Sarepta gene therapy
169
views
FDA advisers vote 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.’s gene therapy for Duchenne muscular dystrophy.
FDA advisers vote 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.’s gene therapy for Duchenne muscular dystrophy.

Comments

https://stocktradingwebsites.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!